PD15 (g/L) | Prolastin (n = 36) | Placebo (n = 35) |
---|---|---|
Change from baseline to last CT scan (mean ± SD) | -2.895 ± 4.739 | -4.124 ± 4.147 |
Change from baseline to last CT scan (LS mean [SE]) | -2.645 (0.526) < 0.0001a | -4.117 (0.539) < 0.0001a |
Estimated treatment difference between LS mean changes from baseline (95% CI) | 1.472 (0.009, 2.935) | |
p value for treatment differenceb | 0.049 | |
MLD (g/L) | Prolastin (n = 36) | Placebo (n = 35) |
Change from baseline to last CT scan (mean ± SD) | -2.115 ± 7.937 | -3.289 ± 5.949 |
Change from baseline to last CT scan (LS mean [SE]) | -1.911 (0.788) 0.0181a | -3.313 (0.801) 0.0001a |
Estimated treatment difference between LS mean changes from baseline (95% CI) | 1.402 (-0.782, 3.586) | |
p value for treatment differenceb | 0.204 | |
VI-910 (%) | Prolastin (n = 36) | Placebo (n = 35) |
Change from baseline to last CT scan (mean ± SD) | 1.761 ± 4.511 | 2.209 ± 3.378 |
Change from baseline to last CT scan (LS mean [SE]) | 1.643 (0.508) 0.0019a | 2.254 (0.517) < 0.0001a |
Estimated treatment difference between LS mean changes from baseline (95% CI) | -0.611 (-2.019, 0.797) | |
p value for treatment differenceb | 0.389 | |
VI-950 (%) | Prolastin (n = 36) | Placebo (n = 35) |
Change from baseline to last CT scan (mean ± SD) | 1.994 ± 3.307 | 2.315 ± 2.578 |
Change from baseline to last CT scan (LS mean [SE]) | 1.924 (0.411) < 0.0001a | 2.356 (0.420) < 0.0001a |
Estimated treatment difference between LS mean changes from baseline (95% CI) | -0.432 (-1.573, 0.709) | |
p value for treatment differenceb | 0.452 |